The largest “retrospective” analysis of Hydroxychloroquine (not a “gold standard” double blind, placebo controlled, clinical trial) in the Henry Ford System’s 6 Hospitals in Detroit shows that giving the drug by itself to patients who were 56% African-American and without severe prior heart conditions cuts the fatality rate in half.
In a large-scale retrospective analysis of 2,541 patients hospitalized between March 10 and May 2, 2020 across the system’s six hospitals, the study found 13% of those treated with hydroxychloroquine alone died compared to 26.4% not treated with hydroxychloroquine. None of the patients had documented serious heart abnormalities; however, patients were monitored for a heart condition routinely pointed to as a reason to avoid the drug as a treatment for COVID-19.
The study was published today in the International Journal of Infectious Diseases, the peer-reviewed, open-access online publication of the International Society of Infectious Diseases (ISID.org).
Patients treated with hydroxychloroquine at Henry Ford met specific protocol criteria as outlined by the hospital system’s Division of Infectious Diseases.
The vast majority received the drug soon after admission; 82% within 24 hours and 91% within 48 hours of admission. All patients in the study were 18 or over with a median age of 64 years; 51% were men and 56% African American.
End quote
Most of the previous published news about Hydroxychloroquine were “Meta-analysies” that tried to use computer techniques to combine several smaller studies run by entirely different researchers who used different guidelines.
Last edited by 360view; 07/07/2007:48 AM. Reason: Spelling
